Liu Meng-yuan, Hu Xue-ping, Xie Mian, Jiang Si-jing, Li Lu-jun, Liu Dong-xu, Yang Xiao-song
Center for Infection and Immunity Research, School of Life Sciences, Hubei University, Youyi Road 368, Wuhan, 430062, China,
Biotechnol Lett. 2014 Dec;36(12):2425-31. doi: 10.1007/s10529-014-1630-2. Epub 2014 Aug 17.
Specific targeting of tumor necrosis factor (TNF)-α antagonist to the inflamed site could increase its efficacy and reduce side-effects. Here, we constructed a bispecific diabody (BsDb) that targets TNF-α and ED-B-containing fibronectin, a fibronectin isoform specifically expressed in the pannus of the inflamed synovium in rheumatoid arthritis. BsDb was secreted from Pichia pastoris as functional protein and was purified to homogeneity. BsDb could simultaneously bind to human TNF-α and B-FN and neutralize TNF-α action. Additionally, BsDb showed a significant gain both in the antigen-binding affinity and in TNF-α-neutralizing ability as compared to its original antibodies, L19 and anti-TNF-α scFv, which were produced in E. coli. BsDb was constructed and was endowed with enhanced bioactivities and improved production processing. Therefore, it holds great potential for in vivo applications.
将肿瘤坏死因子(TNF)-α拮抗剂特异性靶向炎症部位可提高其疗效并减少副作用。在此,我们构建了一种双特异性双抗体(BsDb),其靶向TNF-α和含ED-B的纤连蛋白,后者是类风湿关节炎炎症滑膜血管翳中特异性表达的一种纤连蛋白异构体。BsDb作为功能性蛋白从毕赤酵母中分泌出来,并纯化至均一。BsDb可同时结合人TNF-α和B-FN并中和TNF-α的作用。此外,与在大肠杆菌中产生的原始抗体L19和抗TNF-α单链抗体片段(scFv)相比,BsDb在抗原结合亲和力和TNF-α中和能力方面均有显著提高。BsDb已构建完成,并具有增强的生物活性和改进的生产工艺。因此,它在体内应用方面具有巨大潜力。